Class Action Lawsuit Filed Against Ardelyx Over Alleged Misleading Statements
A class action lawsuit has been filed against Ardelyx, Inc. (NASDAQ: ARDX) and certain officers by Bronstein, Gewirtz & Grossman LLC on behalf of investors who purchased the company's securities between January 13, 2025, and August 6, 2026. The lawsuit alleges that defendants made false or misleading statements regarding Ardelyx’s commercial performance for its products XPHOZAH and IBSRELA by failing to disclose increasing payer-related access barriers affecting patient prescriptions. The complaint claims these issues included more stringent prior authorization requirements slowing new-patient starts, which negatively impacted the company's growth prospects. Investors are being encouraged to join the case before November 16, 2026, and may seek a share of any recovery without serving as lead plaintiff. The law firm is representing investors on a contingency fee basis. The lawsuit could have significant implications for Ardelyx’s stock price and corporate reputation if it proceeds further in court.
Tickers: $ARDX
Topics: financial_disclosure investor_rights securities_laws